Abivax Gets a $160 Boost: Jefferies Sees 'Differentiated' Obefazimod as UC Game-Changer

Jefferies starts Abivax coverage with Buy rating and $160 target. Views obefazimod as differentiated UC therapy; Q2 maintenance data de-risked for approval path.